Securities Analyst Recommendations: Idera Pharmaceuticals, Inc. (IDRA), Workhorse Group Inc. (WKHS)

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA) tinted loss of -2.7% (-0.07 points) to US$2.52. The volume of 0.24 Million shares climbed down over an trading activity of 343.18 Million shares. EPS ratio determined by looking at last 12 month figures is -2.48. Over the same time span, the stock marked US$17.12 as its best level and the lowest price reached was US$2.25. The corporation has a market cap of US$61.99 Million.

Idera Pharmaceuticals, Inc. (NASDAQ:IDRA)’s earnings per share has been growing at a 12.4 percent rate over the past 5 year when average revenue increase was noted as 77.6 percent. The return on equity ratio or ROE stands at -68.4 percent while most common profitability ratio return on investment (ROI) was -61.6 percent. The company’s institutional ownership is monitored at 46.4 percent. The company’s net profit margin has achieved the current level of 0 percent and possesses 0 percent gross margin.

Daily Analyst Recommendations

A number of key analysts, polled by FactSet, shared their views about the current stock momentum. The forecast of 2 surveyed investment analysts covering the stock advises investors to Buy stake in the company. At present, 0 analysts call it Sell, while 0 think it is Hold. Recently, analysts have updated the overall rating to 1.71. 5 analysts recommended Overweight these shares while 0 recommended Underweight, according to FactSet data.

Workhorse Group Inc. (NASDAQ:WKHS) is worth US$56.57 Million and has recently risen 0.03% to US$1. The latest exchange of 0.11 Million shares is below its average trading activity of 283.88 Million shares. The day began at US$0 but the price moved to US$0 at one point during the trading and finally capitulating to a session high of US$0. The stock tapped a 52-week high of US$3.31 while the mean 12-month price target for the shares is US$3.25.

Currently, the stock carries a price to earnings ratio of 0, a price to book ratio of 25, and a price to sales ratio of 8.98. For the past 5 years, the company’s revenue has grown 109%, while the company’s earnings per share has grown 4.4%. With an institutional ownership near 9.2%, it carries an earnings per share ratio of -0.56.

Inside Look At Analysts Reviews

Latest analyst recommendations could offer little help to investors. The stock is a Buy among 0 brokerage firms polled by Factset Research. At present, 0 analysts recommended Holding these shares while 0 recommended sell, according to FactSet data. 0 analysts call it Underweight, while 2 think it is Overweight. Recently, investment analysts covering the stock have updated the mean rating to 2.